Patents by Inventor Daniel H. Golwyn

Daniel H. Golwyn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 5147872
    Abstract: Methods and means for treating psoriasis, as well as Crohn's disease and other HLA-related disorders, to abate their symptoms, with a pharmaceutical diazepine having a component triazolo ring. HLA-related disorders amenable to such treatment include (i) persistent eruptive, granular, or ulcerative conditions of the skin, mouth, or gastrointestinal tract; and (ii) dibilitating inflammatory conditions of the circulatory, muscular, and nervous systems. This treatment alleviates abnormality or unbalance of patients' immune systems, such as an overabundance of natural killer cells and/or an abnormality of helper T-cell/suppressor T-cell ratio, and alleviates the self-cannibilism of the Koebner phenomenon, when present. Triazolobenzodiazepines, such as alprazolam or triazolam, and triazolothienodiazepines, such as etizolam, are examples of preferred treating compositions.
    Type: Grant
    Filed: June 19, 1990
    Date of Patent: September 15, 1992
    Inventor: Daniel H. Golwyn
  • Patent number: 5017575
    Abstract: Means and methods for treating Crohn's disease, as an example of selectively influencing the immune systems of patients afflicted with intractable disorders and thereby abating or relieving the symptoms of such disorders, including many having an autoimmune abnormality or unbalance, such as an excessive concentration of killer T cells or an insufficient concentration of helper T cells or indeed both. A triazolo composition, such as a triazolobenzodiazepine, is administered to such a patient periodically in an amount effective to influence the immune system accordingly and to alleviate such symptoms, whereupon the dosage is gradually reduced to a maintenance level at which the symptoms do not recur but below which such recurrence is likely or certain.
    Type: Grant
    Filed: June 9, 1987
    Date of Patent: May 21, 1991
    Inventor: Daniel H. Golwyn
  • Patent number: 4919916
    Abstract: Treatment of the abuse of those addictive drugs whose apparent mode of operation includes first an enhancement of neurotransmitter activity and subsequently a reduction in that activity--and in accompanying pleasurable sensations--to such an extent that abusers thereof feel compelled to repeat the experience. Examples of abused drugs for which treatment is suitable are amphetamines, cocaine, meperidine, phencyclidine, and new "designer" drugs. The treatment is by daily dosage of phenelzine or equivalent phenylalkylhydrazine so as to effect a degree of monoamine oxidase inhibition incompatible with the abused drug during the period of treatment and for at least a couple weeks thereafter. Concurrent usage is productive of a broad range of dangerous and frightening reactions, described in graphic detail to all patients undergoing such treatment, and any breach of the prohibition confirms the necessity of remaining free of the abused drug throughout.
    Type: Grant
    Filed: November 21, 1988
    Date of Patent: April 24, 1990
    Inventor: Daniel H. Golwyn
  • Patent number: 4786653
    Abstract: Treatment of the abuse of those addictive drugs whose apparent mode of operation includes first an enhancement of neurotransmitter activity and subsequently a reduction in that activity--and in accompanying pleasurable sensations--to such an extent that abusers thereof feel compelled to repeat the experience. Examples of abused drugs for which treatment is suitable are amphetamines, cocaine, meperidine, phencyclidine, and new "designer" drugs. The treatment is by daily dosage of phenelzine or equivalent phenylalkylhydrazine so as to effect a degree of monoamine oxidase inhibition incompatible with the abused drug during the period of treatment and for at least a couple weeks thereafter. Concurrent usage is productive of a broad range of dangerous and frightening reactions, described in graphic detail to all patients undergoing such treatment, and any breach of the prohibition confirms the necessity of remaining free of the abused drug throughout.
    Type: Grant
    Filed: August 24, 1987
    Date of Patent: November 22, 1988
    Inventor: Daniel H. Golwyn